A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates for CYP1A2 and CYP2D6 in Male Subjects With Prostate Cancer

This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer; Pharmacokinetics of Dextromethorphan; Pharmacokinetics of Caffeine
• Intervention / Treatment: Drug: Enzalutamide; Drug: Caffeine; Drug: Dextromethorphan; Drug: Enzalutamide Placebo to Match (PTM)

Detailed Description

This is an open-label, fixed-sequence, crossover drug-drug interaction study in subjects with prostate cancer.

Screening takes place between Day -28 and Day -7, and subjects are admitted to the clinic on Day -1 where they remain until Day 4.

On Day 1, they receive a single oral cocktail containing caffeine and dextromethorphan plus a dose of enzalutamide placebo in order to assess possible effects of excipients of the enzalutamide formulation. On Days 1 to 3 blood samples for pharmacokinetic (PK) assessment are collected. From Days 4 to 54, (or Day 55 if the subject rolls over into the extension study) the subjects take a daily oral dose of enzalutamide. On Day 28, the subjects return to the clinic where a plasma sample is taken to determine enzalutamide PK exposure. From Days 52 to 55 they are re-admitted to the clinic where a plasma sample is collected on Day 52 for enzalutamide PK exposure.On Day 53, subjects receive a single oral cocktail of caffeine and dextromethorphan concomitantly with enzalutamide. PK samples are collected from Days 53 to 55.

From Day 55 onwards, subjects experiencing clinical benefit may roll over into an extension study. Only subjects who enroll into the extension study continue to receive enzalutamide otherwise daily dosing with enzalutamide is discontinued on Day 54.

An End of Study Visit (ESV) takes place approximately 30 days (±7 days) after the last dose of enzalutamide.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• Moldova, Republic of
  • Chisinau, Moldova, Republic of, 2025
    • ARENSIA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Subject is a male aged 18 years old or older (at screening) with histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant setting). Subjects may be on ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or have undergone prior bilateral orchiectomy at screening.
• Subject has progressive disease by prostate-specific antigen (PSA) or imaging.
• Subject has received no more than 2 prior chemotherapy regimens.
• Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Male subject must use a condom if having sex with a pregnant woman.
• Male subject and their female spouse/partners who are of childbearing potential must use 2 acceptable methods of birth control starting at screening and continuing throughout the study period and for 3 months after final study drug administration.
• Subject has an estimated life expectancy of at least 6 months.

Exclusion Criteria:

• Subject has confirmed CYP2D6 poor metabolizer, or CYP2D6 ultrarapid metabolizer status based on genotyping analysis.
• Subject has known metastases in the liver or any hepatic disorder that could affect drug metabolism deemed clinically significant by the investigator after discussion with the sponsor.
• Subject has undergone major surgery within 4 weeks prior to day 1.
• Subject received treatment with chemotherapy within 4 weeks prior to enrollment (day 1 visit) or plans to initiate treatment with chemotherapy during the study.
• Subject uses concomitant medications that are potent inducers and/or inhibitors of CYP1A2, CYP2C8, CYP2D6, or CYP3A4.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1:Caffeine, Dextromethorphan and Enzalutamide; 1-sequence crossover here	Drug: Enzalutamide; Oral; Other Names: Xtandi; MDV3100; ASP9785; Drug: Caffeine; Oral; Other Names: CYP1A2 substrate; Drug: Dextromethorphan; Oral /.L; Other Names: CYP2D6 substrate; Drug: Enzalutamide Placebo to Match (PTM); Oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK measured by Pharmacokinetic parameter Maximum concentration (Cmax)	For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.	Day 1 and Day 53 (28 times)
PK measured by Pharmacokinetic parameter Area under the curve (AUC) from the time of dosing to the last measurable concentration (AUC0-t)	For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.	Day 1 and Day 53 (28 times)
PK measured by PK parameter area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-inf)	For the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.	Day 1 and Day 53 (28 times)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK measured by PK parameters tmax, terminal elimination half-life (t1/2), apparent total systemic clearance after oral dosing (CL/F), apparent volume of distribution during terminal elimination phase (Vz/F) and extrapolated AUC (%AUC)	Tmax is time to maximum concentration. These PK parameters will be measured for the probe substrates (caffeine and dextromethorphan) in combination with enzalutamide PTM and in combination with enzalutamide.	Day 1 and Day 53 (28 times)
PK measured by PK parameters Cmax, AUC0-t, AUC0-inf, %AUC, tmax and t1/2	For 1,7-dimethylxanthine (metabolite caffeine), dextrorphan (metabolite dextromethorphan).	Day 1 and Day 53 (28 times)
PK measured by PK parameters Cmax, trough concentrations (Ctrough) at Days 28, 52, 53, 54 and 55, tmax, AUC during the time interval between consecutive dosing (AUCtau), CL/F (parent only) and peak-to-trough ratio (PTR)	For Enzalutamide, N-desmethyl enzalutamide (M2) and sum of enzalutamide + M2.	Day 28 (± 1 day), and Days 52 to 55 (15 times)
Safety and tolerability measured by vital signs, adverse events, laboratory assessments and electrocardiogram		Screening (Day -28 to Day -7) to ESV (>153 times)

Collaborators and Investigators

• Sponsor: Astellas Pharma Europe B.V.
• Collaborators: Medivation, Inc.

Publications and helpful links

Helpful Links

• Link to results on Astellas Clinical Study Results website

Study record dates

Study Major Dates

• Study Start (Actual): October 2, 2013
• Primary Completion (Actual): February 3, 2014
• Study Completion (Actual): February 3, 2014

Study Registration Dates

• First Submitted: August 22, 2014
• First Submitted That Met QC Criteria: August 22, 2014
• First Posted (Estimate): August 26, 2014

Study Record Updates

• Last Update Posted (Actual): June 27, 2017
• Last Update Submitted That Met QC Criteria: June 26, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; Prostate cancer; Phase 1; Enzalutamide; Caffeine; Dextromethorphan; CYP2D6; Drug-drug interactions; CYP1A2
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Purinergic Antagonists; Purinergic Agents; Respiratory System Agents; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Central Nervous System Stimulants; Antitussive Agents; Dextromethorphan; Caffeine
• Other Study ID Numbers: 9785-CL-0406